Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy

Area of Science:

• Oncology
• Biotechnology
• Microbiology

Background:

• Cancer remains a leading cause of death globally, despite advances in precision therapeutics.
• Cancer drug resistance is a significant barrier to successful treatment outcomes.
• Traditional therapies often fail due to complex resistance mechanisms.

Purpose of the Study:

• To review the primary mechanisms of cancer drug resistance.
• To explore the potential of bacterial-mediated cancer therapy as a novel treatment strategy.
• To highlight how synthetic biology can engineer bacteria to overcome drug resistance.

Main Methods:

• Literature review of cancer drug resistance mechanisms (pharmacokinetics, tumor microenvironment, intrinsic/acquired resistance).
• Analysis of synthetic biology advancements in engineering bacteria for therapeutic applications.
• Evaluation of bacterial properties relevant to cancer treatment (targeting, anti-tumor activity, safety).

Main Results:

• Cancer resistance involves pharmacokinetic, tumor microenvironment, and intrinsic drug resistance mechanisms.
• Bacterial-mediated cancer therapy, revitalized by synthetic biology, shows promise in overcoming these resistance mechanisms.
• Genetically engineered bacteria possess tumor-targeting capabilities, anti-tumor activity, safety, and drug delivery potential.

Conclusions:

• Bacterial-mediated cancer therapy presents a promising strategy to combat drug resistance in cancer treatment.
• Synthetic biology enables the engineering of bacteria as potent and targeted anticancer agents.
• Further research into engineered bacteria could lead to improved cancer therapeutic outcomes.